Whalesbook
Emcure Pharmaceuticals Limited shares fell 3.24% to Rs 1,349.70 as global investment firm Bain Capital reportedly plans to sell up to 2% equity via a block deal estimated at Rs 493 crore. This comes as Emcure also announced a strategic partnership with Novo Nordisk India to launch Poviztra, a semaglutide injection for weight loss, aiming to expand market access and distribution. The company also reported strong Q2 results with 13% revenue and 25% PAT growth.